NSI-189: A Neurogenic Compound for Hippocampal Research
NSI-189 (as free base or phosphate salt) is an investigational benzylpiperazine-aminopyridine compound developed by Neuralstem Inc. for the treatment of major depressive disorder (MDD) and cognitive impairment. Its primary proposed mechanism is stimulation of neurogenesis in the hippocampus — the brain region most closely associated with memory formation and emotional regulation — making it mechanistically distinct from nearly all other cognitive or antidepressant research compounds.
Mechanism: Hippocampal Neurogenesis
NSI-189 promotes the proliferation and differentiation of adult neural stem cells in the subgranular zone of the hippocampus. In animal studies, this is associated with measurable increases in hippocampal volume, improved performance on spatial memory tasks, and indicators of improved mood regulation. The compound is proposed to work through a mechanism distinct from BDNF pathway activation, though the precise molecular target has not been fully characterized. This makes NSI-189 a valuable tool compound for research into activity-independent neurogenesis.
Phase 1 and Phase 2 Human Data
Phase 1 trials established NSI-189’s safety and tolerability in healthy volunteers at doses up to 100 mg/day. A randomized Phase 2 trial by Fava et al. (2016) in 220 MDD patients demonstrated that NSI-189 at 40 mg/day showed statistically significant improvement in depression symptoms on several scales, with the most pronounced effects in patients with moderate depression. [PMID: 26830140] The Phase 2 trial did not meet its primary endpoint, but the secondary and exploratory data have maintained scientific interest in the compound — particularly for cognitive dimensions of depression.
NSI-189 vs Other Neurological Compounds
NSI-189 is mechanistically different from glutamatergic nootropics like Noopept, Sunifiram, and Unifiram, all of which act acutely on receptor signaling. NSI-189 produces structural changes over time, making it more appropriate for chronic treatment models. It is also compared to dopaminergic compounds like 9-ME-BC, which targets neuroregeneration through a different neurotransmitter system.
Available Formulations
For laboratory research use only.
